IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Overall MarketRank^™

1.74 out of 5 stars

Business Services Sector

64th out of 442 stocks

Commercial Physical Research Industry

4th out of 42 stocks

2.5 Analyst's Opinion

Consensus Rating
IQVIA has received a consensus rating of Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $241.81, IQVIA has a forecasted upside of 3.2% from its current price of $234.39.
Amount of Analyst Coverage
IQVIA has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
IQVIA has received 555 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IQVIA has received 465 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IQVIA has received 54.41% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IQVIA and other stocks. Vote “Outperform” if you believe IQV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IQVIA does not currently pay a dividend.
Dividend Growth
IQVIA does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IQVIA insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.00% of the stock of IQVIA is held by insiders.
Percentage Held by Institutions
87.15% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for IQVIA are expected to grow by 24.49% in the coming year, from $5.84 to $7.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IQVIA is 257.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.05.
Price to Earnings Ratio vs. Sector
The P/E ratio of IQVIA is 257.57, which means that it is trading at a more expensive P/E ratio than the Business Services sector average P/E ratio of about 35.00.
Price to Earnings Growth Ratio
IQVIA has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
IQVIA has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

IQVIA (NYSE:IQV) Frequently Asked Questions

Is IQVIA a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IQVIA stock.
View analyst ratings for IQVIA or view top-rated stocks.

What stocks does MarketBeat like better than IQVIA?

Wall Street analysts have given IQVIA a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IQVIA wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IQVIA's next earnings date?

IQVIA is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for IQVIA.

How were IQVIA's earnings last quarter?

IQVIA Holdings Inc. (NYSE:IQV) posted its quarterly earnings results on Thursday, April, 22nd. The medical research company reported $2.18 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.33. The medical research company had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.18 billion. IQVIA had a net margin of 1.61% and a trailing twelve-month return on equity of 18.03%. The business's revenue was up 23.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.50 earnings per share.
View IQVIA's earnings history.

How has IQVIA's stock been impacted by Coronavirus (COVID-19)?

IQVIA's stock was trading at $125.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IQV shares have increased by 87.0% and is now trading at $234.48.
View which stocks have been most impacted by COVID-19.

What guidance has IQVIA issued on next quarter's earnings?

IQVIA updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of 8.500-8.750 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.040. The company issued revenue guidance of $13.20 billion-$13.50 billion, compared to the consensus revenue estimate of $12.83 billion.

What price target have analysts set for IQV?

14 analysts have issued 12 month target prices for IQVIA's shares. Their forecasts range from $156.00 to $273.00. On average, they anticipate IQVIA's stock price to reach $241.81 in the next year. This suggests a possible upside of 3.1% from the stock's current price.
View analysts' price targets for IQVIA or view top-rated stocks among Wall Street analysts.

Who are IQVIA's key executives?

IQVIA's management team includes the following people:

Mr. Ari Bousbib, Chairman, Pres & CEO (Age 60, Pay $8.76M)
Mr. Ronald E. Bruehlman, Exec. VP & CFO (Age 60, Pay $1.67M) (LinkedIn Profile)
Mr. Kevin C. Knightly, Pres of Technology & Commercial Solutions (Age 60, Pay $1.23M)
Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 57, Pay $1.24M) (LinkedIn Profile)
Mr. W. Richard Staub III, Pres of R&D Solutions (Age 58, Pay $1.45M) (LinkedIn Profile)
Mr. Emmanuel N. Korakis, Sr. VP, Corp. Controller & Principal Accounting Officer (Age 47)
Dr. Jeffrey A. Spaeder, Sr. VP, Global Chief Medical & Scientific Officer (LinkedIn Profile)
Mr. Alejandro Martinez, Chief Information Officer
Andrew Markwick, Sr. VP of Investor Relations & Treasury
Ms. Trudy Stein, Chief HR Officer & Exec. VP (LinkedIn Profile)

What is Ari Bousbib's approval rating as IQVIA's CEO?

1,545 employees have rated IQVIA CEO Ari Bousbib on Glassdoor.com. Ari Bousbib has an approval rating of 84% among IQVIA's employees.

Who are some of IQVIA's key competitors?

Some companies that are related to IQVIA include Bitcoin Group (BTGGF), Exact Sciences (EXAS), Incyte (INCY), Charles River Laboratories International (CRL), PPD (PPD), ICON Public (ICLR), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), Medpace (MEDP), Precigen (PGEN), National Research (NRC), Anavex Life Sciences (AVXL), Starpharma (SPHRY) and Luna Innovations (LUNA).
View all of IQV's competitors.

What other stocks do shareholders of IQVIA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IQVIA investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG), Alibaba Group (BABA), PayPal (PYPL), salesforce.com (CRM) and Accenture (ACN).

What is IQVIA's stock symbol?

IQVIA trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are IQVIA's major shareholders?

IQVIA's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (3.48%), Sumitomo Mitsui Trust Holdings Inc. (0.60%), Cantillon Capital Management LLC (0.50%), Assenagon Asset Management S.A. (0.39%), Swiss National Bank (0.38%) and TCW Group Inc. (0.32%). Company insiders that own IQVIA stock include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and Ronald E Bruehlman.
View institutional ownership trends for IQVIA.

Which institutional investors are selling IQVIA stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Bank of Nova Scotia, TCW Group Inc., Ardevora Asset Management LLP, Sumitomo Mitsui Trust Holdings Inc., Los Angeles Capital Management LLC, UNIVEST FINANCIAL Corp, Associated Banc Corp, and Rhumbline Advisers. Company insiders that have sold IQVIA company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, and Ronald A Rittenmeyer.
View insider buying and selling activity for IQVIA or view top insider-selling stocks.

Which institutional investors are buying IQVIA stock?

IQV stock was acquired by a variety of institutional investors in the last quarter, including Cantillon Capital Management LLC, Alliancebernstein L.P., Artemis Investment Management LLP, Royal London Asset Management Ltd., Howard Capital Management Group LLC, Envestnet Asset Management Inc., Wesbanco Bank Inc., and Robeco Institutional Asset Management B.V.. Company insiders that have bought IQVIA stock in the last two years include John G Danhakl, and Ronald E Bruehlman.
View insider buying and selling activity for IQVIA or or view top insider-buying stocks.

How do I buy shares of IQVIA?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IQVIA's stock price today?

One share of IQV stock can currently be purchased for approximately $234.48.

How much money does IQVIA make?

IQVIA has a market capitalization of $44.94 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis.

How many employees does IQVIA have?

IQVIA employs 70,000 workers across the globe.

Does IQVIA have any subsidiaries?

The following companies are subsidiares of IQVIA: 159 SOLUTIONS, 159 Technology Solutions Private Ltd, AHM Global Operations Inc., AHM Global Services LLC, AHM Logistics Inc. (Canada), AIECO IT Solutions India Private Ltd., ALIMED Egeszsegugyi Szolgaltato Kft., Advanced Health Media LLC, Advanced Health Media Services, Aileron Solutions, Albatross Financial Solutions Limited, Appature, Ardentia International Limited, Ascott Sales Integration, Asesorias IQVIA Solutions Chile Limitada, Asserta Centroamerica Medicion de Mercados, BUZZEOPDMA LLC, Battaerd Mansley Pty. Ltd., Benefit Canada, Benefit Holding, BioFortis, CDS - Center de Service SAS, COORDINATED MANAGEMENT SYSTEM, CRM Health Korea Ltd., CSD Health Korea Ltd., Cambridge Pharma Consultancy, Cambridge Pharma Consultancy Limited, Cegedim Venezuela C.A., Cenduit (India) Services Private Company Limited, Cenduit Limited, Cenduit Mauritius Holdings Company, Clinical Financial Services, Clinical Lab Minority Shareholder Limited, Coordinated Management Holdings L.L.C., Coté Orphan, Coté Orphan Consulting UK Limited, DATA NICHE ASSOCIATES, Datadina Ecuador S.A., Dataline Software Limited, Datec Industria e Comercio, Dimensiions Healthcare LLC, Drug Dev Inc., DrugDev, DrugDev Limited, EA Institute L.L.C., ENTERPRISE ASSOCIATES, EPS Research Limited, EPS Software Limited, Epernicus, Forcea NV, Foresight Group International UK LTD, Foresight Group Japan G.K., Foresight IT Solutions Consulting India Private Limited, GRACE DATA CORPORATION, Global Crown Investment Limited, HIGHPOINT SOLUTIONS, Hospital Marketing Services Ltd., Hotel Lot C-8B, IMS (GIBRALTAR) HOLDING LIMITED, IMS (UK) Pension Plan Trustee Company Limited, IMS AB, IMS CHINAMETRIK INC., IMS HEALTH GROUP LIMITED, IMS HEALTH KOREA LTD, IMS HEALTH KOREA LTD., IMS HEALTH PUERTO RICO INC., IMS HEALTH TAIWAN LTD., IMS Health (Australia) Partnership, IMS Health Analytics Services Private Limited, IMS Health Bangladesh Limited, IMS Health Bolivia S.R.L., IMS Health Cyprus LTD, IMS Health Egypt Limited, IMS Health Information Solutions Argentina S.A., IMS Health Information Solutions Australia Pty. Ltd, IMS Health Information Solutions India Private Ltd., IMS Health Information Solutions Japan K.K., IMS Health Lanka (Private) Limited, IMS Health Networks Limited, IMS Health Pakistan (Private) Limited, IMS Health Paraguay SRL, IMS Health Surveys Limited, IMS Health Technology Solutions (China) Co. Ltd., IMS Health Technology Solutions Australia Pty. Ltd, IMS Health Technology Solutions Colombia Ltda., IMS Health Technology Solutions Holdings AB, IMS Health Technology Solutions Hungary Ltd., IMS Health Technology Solutions India Private Ltd., IMS Health Technology Solutions Japan K.K., IMS Health Technology Solutions Kazakhstan, IMS Health Technology Solutions LLC, IMS Health Technology Solutions Sweden AB, IMS Health Technology TUNISIA, IMS Health Tunisia sarl, IMS Health Uruguay S.A., IMS Health de Venezuela C.A., IMS Holdings (U.K.) Limited, IMS Hospital Group Limited, IMS Information Solutions Medical Research Limited, IMS Information Solutions UK Ltd., IMS International (Proprietary) Limited, IMS Market Research Consult (Beijing), IMS Meridian Limited, IMS Meridian Research Limited, IMS Republica Dominicana, IMS SOFTWARE SERVICES LTD., IMS Technology Solutions UK Limited, INTERCONTINENTAL MEDICAL STATISTICS INTERNATIONAL, IPP Informacion Promocional y Publicitaria S.A. de C.V., IPP Technology Solutions Mexico SA de CV (FKA Cegedim Mexico SA de CV), IQVA Romania S.R.L., IQVIA (Thialand) Co. Ltd., IQVIA AB, IQVIA AG, IQVIA AG (Mexico Branch), IQVIA AG (UK Branch), IQVIA Adriatic d.o.o. za Konzalting, IQVIA Asia Pacific Commercial Holdings LLC, IQVIA Beteiligungs-gesellschaft mbH, IQVIA BioSciences Holdings LLC, IQVIA CHINAMETRIK INC., IQVIA COMMERCIAL FINANCE INC., IQVIA COMMERCIAL INDIA HOLDINGS CORP., IQVIA COMMERCIAL LICENSING ASSOCIATES LLC, IQVIA COMMERCIAL SERVICES LLC, IQVIA COMMERCIAL TRADING CORP., IQVIA Clinical AB, IQVIA Commercial Deutschland GmbH, IQVIA Commercial GmbH & Co. OHG, IQVIA Commercial I LLC, IQVIA Commercial Software GmbH, IQVIA Commercial Sp. z.o.o., IQVIA Commerical Consulting Sp. z.o.o., IQVIA Consulting Solutions bvba, IQVIA Consulting and Information Services India Private Limited, IQVIA Finance Ireland Designated Activity Company, IQVIA GOVERNMENT SOLUTIONS INC., IQVIA Healthcare QFC branch, IQVIA Hellas Technology Solutions S.A., IQVIA Holdings France SAS, IQVIA IES (UK) Limited, IQVIA IES Brasil Ltda., IQVIA IES Europe Limited, IQVIA IES European Holdings, IQVIA IES Italia S.r.l., IQVIA IES OY, IQVIA IES Overseas Holdings Limited, IQVIA IES Portugal, IQVIA IES Portugal Unipressoal Ltda., IQVIA IES Puerto Rico Inc., IQVIA II Technology Solutions Portugal, IQVIA INC., IQVIA INFORMATION MEDICAL STATISTICS (ISRAEL) LTD., IQVIA Information, IQVIA Information Solutions (China) Co., IQVIA Information Solutions GmbH, IQVIA Informations Solutions France SAS, IQVIA Istanbul Saglik Hizmetler Arastirma ve Danismanlik Limited Sirketi, IQVIA Korea Co. Ltd., IQVIA LTD, IQVIA Market Intelligence LLC, IQVIA Marktforschung GmbH, IQVIA Maroc SARL, IQVIA Mauritius Holdings, IQVIA Medical Communications & Consulting, IQVIA Medical Development (Dalian) Co., IQVIA Medical Education Inc., IQVIA Medical Radar AB, IQVIA Operations France SAS, IQVIA PHARMA Inc., IQVIA Partners AS, IQVIA Pharma Services Corp., IQVIA Pharmaceutical Marketing Services Ltd., IQVIA Phase One Services LLC, IQVIA RDS (India) Private Limited, IQVIA RDS (Pty.) Limited, IQVIA RDS AG, IQVIA RDS Argentina S.A., IQVIA RDS Asia Inc., IQVIA RDS Austria GmbH, IQVIA RDS BT Inc., IQVIA RDS Brasil Ltda., IQVIA RDS Bulgaria EOOD, IQVIA RDS Canada ULC, IQVIA RDS Chile, IQVIA RDS Colombia S.A.S., IQVIA RDS Consulting Inc., IQVIA RDS ESTONIA OU, IQVIA RDS East Asia Pte. Ltd., IQVIA RDS Eastern Holdings GmbH, IQVIA RDS Finland OY, IQVIA RDS France SAS (formerly, IQVIA RDS Funding LLC, IQVIA RDS GesmbH, IQVIA RDS GesmbH Greek Branch, IQVIA RDS Guatemala S.A., IQVIA RDS Holdings, IQVIA RDS Hong Kong Limited, IQVIA RDS ISRAEL LTD., IQVIA RDS Inc., IQVIA RDS Ireland (Finance) Ltd., IQVIA RDS Ireland Ltd., IQVIA RDS Italy Srl, IQVIA RDS Latin America LLC, IQVIA RDS Latvia SIA, IQVIA RDS Magyarorszag Gyogyszerfejlesztesi es Tanacsado Kft., IQVIA RDS Malaysia Sdn. Bhd., IQVIA RDS Moscow, IQVIA RDS Novosibirsk, IQVIA RDS Panama Inc., IQVIA RDS Peru S.r.l., IQVIA RDS Philippines Inc., IQVIA RDS Poland Sp. Zoo, IQVIA RDS Pty. Limited, IQVIA RDS Slovakia s.r.o., IQVIA RDS Spain, IQVIA RDS Spain S.L., IQVIA RDS St. Petersburg, IQVIA RDS Support Sarl, IQVIA RDS Switzerland sarl, IQVIA RDS Taiwan Ltd., IQVIA RDS Transfer LLC, IQVIA RDS UAB, IQVIA RDS UK Holdings Ltd., IQVIA RDS and Integrated Services Belgium NV, IQVIA RDS d.o.o. Beograd, IQVIA SOLUTIONS ASIA PTE. LTD., IQVIA SOLUTIONS CANADA INC., IQVIA SOLUTIONS JAPAN K.K., IQVIA SOLUTIONS OPERATIONS CENTER PHLIPPINES INC., IQVIA SOLUTIONS PHILIPINES, IQVIA SOLUTIONS PHILIPPINES, IQVIA Services Japan K.K., IQVIA Solutions (NZ) Limited, IQVIA Solutions (Pty.) Ltd., IQVIA Solutions Argentina S.A., IQVIA Solutions Australia Holdings Pty. Ltd., IQVIA Solutions Australia Pty. Ltd., IQVIA Solutions B.V., IQVIA Solutions Belgium S.P.R.L., IQVIA Solutions Bulgaria EOOD, IQVIA Solutions Colombia S.A., IQVIA Solutions Consulting Myanmar Company Limited, IQVIA Solutions Denmark AS, IQVIA Solutions Enterprise Management Consulting (Shanghai) Co., IQVIA Solutions Finance B.V., IQVIA Solutions Finance UK I Ltd., IQVIA Solutions Finance UK II Ltd., IQVIA Solutions Finance UK III Ltd., IQVIA Solutions Finance UK V Ltd., IQVIA Solutions Finland OY, IQVIA Solutions Global Holdings UK Ltd., IQVIA Solutions GmbH, IQVIA Solutions HQ Ltd., IQVIA Solutions Holdings (Pty.) Ltd., IQVIA Solutions Hong Kong Limited, IQVIA Solutions Ireland Limited, IQVIA Solutions Italy W.r.l., IQVIA Solutions Kazakhstan LLC, IQVIA Solutions LLC, IQVIA Solutions Malaysia Sdn. Bhd., IQVIA Solutions Norway AS, IQVIA Solutions Pharmaceutical SRL, IQVIA Solutions Portugal, IQVIA Solutions Regional Pte. Ltd., IQVIA Solutions Services Ltd., IQVIA Solutions Sweden AB, IQVIA Solutions UK Investments Ltd., IQVIA Solutions UK Limited, IQVIA Solutions a.s., IQVIA Solutions del Peru S.A., IQVIA Solutions do Brasil Ltda., IQVIA Solutions s.r.o., IQVIA Soluçoes de Tecnologia DO Brazil Ltda., IQVIA Staff Services Sp.A., IQVIA TRANSPORTATION SERVICES CORP., IQVIA Technology Services Ltd., IQVIA Technology Solutions Egypt LLC, IQVIA Technology Solutions Finland OY, IQVIA Technology Solutions Poland SP. z.o.o., IQVIA Technology Solutions Romania Srl, IQVIA Technology Solutions S.R.O. Branch Bulgaria, IQVIA Technology Solutions Ukraine LLC, IQVIA Technology Solutions s.r.o., IQVIA Technology and Services AG, IQVIA Tibbi Istatistik Ticaret ve Musavirlik Ltd. Sirketi, IQVIA Trading Management Inc., IQVIA World Publications Ltd., IQVIA Zagreb d.o.o., Iasist Holdco Limited, Iasist Potugal, Iasist SAU Agencia en Chile, Iasist Sociedad Anonima Unipersonal, Impact RX, Infocus Health Limited, Infopharm Ltd., Innovex Holdings I LLC, Innovex Merger Corp., Innovex Saglik Hizmetleri Arastirma ve Danismanlik Ticaret Limited Sirketi, Innovex Saglik Urunleri Pazarlame ve Hizmet Danismanlik Anonim Sirketi, Institute of Medical Communications NCO, Interstatistik AG, Kun Tai Medical Development Hong Kong Limited, Kun Tuo Medical Research & Development (Beijing) Co. Ltd., Laboratorie Novex Pharma Sarl, Laboratorio Commuq Pharma SL, Linguamatics, M&H Informatics (BD) LTD., M-TAG Australia Pty. Ltd., MED-VANTAGE, MG Recherche, Mecurial Insights Holding Pty. Ltd., Mecurial Insights Pty. Ltd., Mercados Y Analisis, Meridian Research Vietnam Ltd., Nordisk Medicin Information AB, Novella Clinical LLC, Novella Clinical Ltd., Novex Pharma Gmbh, Novex Pharma Laboratorio S.L., Novex Pharma Limited, Nuevo Health Pty Ltd, Onkodatamed GmbH, Operaciones Centralizadas Latinoamericana Limitada, Optimum Contact Limited, Outcome Sciences LLC, PILGRIM SOFTWARE HOLDING B.V., POLARIS MANAGEMENT PARTNERS LLC, POLARIS SOLUTIONS LLC, PR Editions S.A.S., PT IMS Health Indonesia, PT Quintiles Indonesia, Penderwood Limited, PharmARC Consulting Services GmbH, PharmARC Inc., Pharma Deals Limited, Pharma Strategy Group Ltd., Pharmadata s.r.o., Pharmaforce, Pilgrim Quality Solutions EMEA BV, Pilgrim Software Asia PVT, Polaris Solutions BV, Polaris Solutions Ltd., Primeum IQVIA SAS, Privacy Analytics Inc., Professional Pharmaceutical Marketing Services (Pty.) Ltd., Pygargus AB, Q Squared Solutions (Beijing) Co. Ltd., Q Squared Solutions (India) Private Limited, Q Squared Solutions (Quest) LLC, Q Squared Solutions (Quest) Limited, Q Squared Solutions (Shanghai) Co. Ltd., Q Squared Solutions B.V., Q Squared Solutions BioSciences LLC, Q Squared Solutions China (Quest) Limited, Q Squared Solutions China Limited, Q Squared Solutions Expression Analysis LLC, Q Squared Solutions Holdings B.V., Q Squared Solutions Holdings LLC, Q Squared Solutions Holdings Limited, Q Squared Solutions K.K., Q Squared Solutions LLC, Q Squared Solutions Limited, Q Squared Solutions Proprietary Limited, Q Squared Solutions Pte. Ltd., Q Squared Solutions S.A., Q2 Metrics, QIMS Pharma Services SA DE CV, QUINTILES MEXICO, QUINTILESIMS EUROPEAN HOLDINGS II C.V., Qcare Site Services, Quintiles B.V., Quintiles Benin Ltd., Quintiles Clindata (Pty.) Limited, Quintiles Clindepharm (Pty.) Limited, Quintiles Clinical and Commercial Nigeria Limited, Quintiles Commercial ApS, Quintiles Commercial Germany GmbH, Quintiles Commercial Rus LLC, Quintiles Commercial South Africa (Pty) Limited, Quintiles Commercial US. Inc., Quintiles Costa Rica S.A., Quintiles Czech Republic, Quintiles Denmark, Quintiles East Africa Limited, Quintiles Egypt LLC, Quintiles Enterprise Management (Shanghai) Co. Ltd., Quintiles Finance Sarl, Quintiles Finance Uruguay, Quintiles GmbH, Quintiles Holdings S.a.r.l., Quintiles IMS European Holdings C.V., Quintiles Lanka Private Limited, Quintiles Latin America Inc., Quintiles Luxembourg European Holding, Quintiles Luxembourg European Holding S.a.r.l., Quintiles Luxembourg France Holdings SARL, Quintiles Medical Development (Shanghai) Co. Ltd., Quintiles Netherlands, Quintiles New Zealand, Quintiles Norway, Quintiles Phase One Clinical Trials India Private Limited, Quintiles Russia LLC, Quintiles S.a.r.l., Quintiles Site Services, Quintiles South Africa (PTY.) Limited, Quintiles UK (Japan Holdings) Limited, Quintiles Ukraine, Quintiles Vietnam, Quintiles West Africa Limited, RX India LLC, Radar Acquisition Blocker, Redsite Limited, Reportive SA, STI Technologies Limited, Schwarzeck Verlag GmbH, Secureconsent, Shanghai IMS Market Research Co. Ltd., Source Informatics Limited, Spartan Leasing Corporation, Statfinn Oy, Strategique Sante, THE AMUNDSEN GROUP, Targeted Molecular Diagnostics, Tarius A/S, Temas Srl - Società Unipersonale, TforG Connect BVBA, Themis Limited, UAB IQVIA Commercial, VALUEMEDICS RESEARCH, VCG&A Inc., and iGuard.

When was IQVIA founded?

IQVIA was founded in 2016.

What is IQVIA's official website?

The official website for IQVIA is www.iqvia.com.

Where are IQVIA's headquarters?

IQVIA is headquartered at 4820 EMPEROR BOULEVARD, DURHAM NC, 27703.

How can I contact IQVIA?

IQVIA's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

IQVIA Stock Forecast, Price & News

Adding

Adding

Adding IQVIA Holdings Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links

Headlines

About IQVIA

MarketRank™

Overall MarketRank™